To receive CME credit for this program:
- Read the CME information and mark the checkbox confirming you have read the disclosures to download the PDF file below
- Review the article and illustration
- Login or register at the CME post test website (http://www.bucmetest.com)
- Locate the course code (listed below) and take the appropriate test
Jointly sponsored by Boston University School of Medicine and the Angiogenesis Foundation
ACCREDITATION STATEMENT
This CME activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through Joint Sponsorship of Boston University School of Medicine and the Angiogenesis Foundation. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
PROGRAMS AND FACULTY
Dietary Impact on Cancer Epigenetics and Angiogenesis
Nancy Emenaker, Ph.D., R.D.
Program Director
National Cancer Institute/National Institutes of Health
CME Course Code: I.ANG11bstdiet
Clinical Markers of Antiangiogenic Therapy in the Platelet Proteome
Giannoula Lakka Klement, M.D., FRCPC
Assistant Professor in Medicine
Tufts University School of Medicine
CME Course Code: I.ANG11bstplate
Sequential Angiogenenic Blockade for the Treatment of Recurrent Cancer
Joyce F. Liu, M.D., M.P.H.
Instructor of Medicine
Dana Farber Cancer Institute
CME Course Code: I.ANG11bstblock
Controversies of Anti-VEGF Therapy for Breast Cancer
Erica L. Mayer, M.D., M.P.H.
Instructor in Medicine
Harvard Medical School Dana Farber Cancer Institute
CME Course Code: I.ANG11bstvegf
Intergrin Targeting for Advanced Malignancies
David A. Reardon, M.D.
Associate Professor
Duke University Medical Center
CME Course Code: I.ANG11bstadv
Antiangiogenic Therapy Response vs. Pseudoresponse in Brain Cancer
A. Gregory Sorensen, M.D.
Co-Director, Martinos Center for Biomedical Imaging Massachusetts General Hospital
CME Course Code: I.ANG11bstbc
Endothelial Progenitor Cells as Systemic Sensors of Breast Cancer
Raj K, Tiwari, Ph.D.
Professor of Microbiology and Immunology
New York Medical College
CME Course Code: I.ANG11bstendo
Biomarker Identification in Antiangiogenesis Clinical Trials
Peter M. Wilson, Ph.D.
Doctoral Research Associate
Keck School of Medicine
USC Norris Comprehensive Cancer Center
CME Course Code: I.ANG11bstid
CREDIT DESIGNATION
This CME Internet activity is comprised of a series of 8 individual webcasts. Boston University School of Medicine designates each webcast a maximum of
0.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Credit will be awarded provided this activity is used and completed according to instructions and a score of 70% or better is achieved. A certificate of credit will be issued to those who successfully complete the examination.
RELEASE AND EXPIRATION
Date of original release: July 8, 2011
Date of expiration: July 7, 2012
TARGET AUDIENCE
Practicing oncologists in the U.S., researchers and medical students
HEALTHCARE GAP
Even with approved agents on the market, antiangiogenic therapy represents a relatively new approach to cancer management, which leads to a critical need to rapidly and effectively educate physicians about: the scientific and clinical rationale for treating tumor angiogenesis; the pathways and mechanisms involved in tumor angiogenesis; the strategies by which antiangiogenic agents are being integrated into traditional therapeutic protocols; the efficacy and safety data emerging from well-designed and rigorous clinical studies of antiangiogenic therapy; and how this data can directly be used to improve clinical decision-making and outcomes for cancer patients. In addition, many clinicians were trained before the era of targeted therapies and can be overwhelmed with the intricacies of signal pathways, their interrelationships, and the effects of therapies. Therefore, there is an opportunity to educate clinicians about this complex information using visual graphic communication tools.
PROGRAM LEARNING OBJECTIVES
At the conclusion of this educational activity, clinicians will be able to:
- Summarize angiogenesis-based targets for treating angiogenesis-dependent diseases that improve patient outcomes
- Discuss recent clinical data supporting the use of emerging and approved angiogenesis-based treatments that benefit patients and their advocates
- Interpret safety and efficacy data from advanced and pivotal clinical trials of angiogenesis-based therapies
- Describe and differentiate new strategies integrating angiogenesis agents with current therapies
METHOD OF PARTICIPATION
There are no fees for participating in and receiving credit for this online educational activity. The participant should, in order, read the objectives and faculty disclosures, review the educational content, answer the multiple-choice post-test and complete the evaluation. The Best of Antiangiogenesis Webcast is available on the Angiogenesis Foundation's website (http://www.angio.org) in the CME section. A print version is also available; for more information contact outreach@angio.org. After reviewing the material, CME credits are available through the Boston University School of Medicine's website (http://www.bucmetest.com) by selecting the name of the program (registration required). Course code: I.ANG11BST.
ACKNOWLEDGEMENT OF SUPPORT
This activity is supported by educational grants from Bristol-Myers Squibb, Genentech, Millennium, Pfizer, and Sanofi-Aventis.
COURSE FACULTY
Nancy Emenaker, Ph.D., R.D.
Program Director
National Cancer Institute/National Institutes of Health
Giannoula Lakka Klement, M.D., FRCPC
Assistant Professor in Medicine
Tufts University School of Medicine
Joyce F. Liu, M.D., M.P.H.
Instructor of Medicine
Dana Farber Cancer Institute
Erica L. Mayer, M.D., M.P.H.
Instructor in Medicine
Harvard Medical School
Dana Farber Cancer Institute
David A. Reardon, M.D.
Associate Professor
Duke University Medical Center
A. Gregory Sorensen, M.D.
Co-Director, Martinos Center for Biomedical Imaging
Massachusetts General Hospital
Raj K, Tiwari, Ph.D.
Professor of Microbiology and Immunology
New York Medical College
Peter M. Wilson, Ph.D.
Doctoral Research Associate
Keck School of Medicine
USC Norris Comprehensive Cancer Center
DISCLOSURE
Boston University School of Medicine asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all relationships with commercial interests. This information is disclosed to CME activity participants. Boston University School of Medicine has procedures to resolve apparent conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.
Nancy Emenaker, Ph.D., R.D.
National Cancer Institute/National Institutes of Health
Dr. Emenaker has nothing to disclose with regard to commercial interests.
Giannoula Lakka Klement, M.D., FRCPC
Tufts University School of Medicine
Dr. Klement has nothing to disclose with regard to commercial interests.
Joyce F. Liu, M.D., M.P.H.
Instructor of Medicine
Dana Farber Cancer Institute
Dr. Liu is a consultant for Sanofi-Aventis
This CME activity contains discussion of published and/or investigational use of bevacizumab (Avastin®), cediranib (AZD2171; Recentin®), pazopanib (Votrient®), sorafenib (Nexavar®), and sunitinib (Sutent®).
Erica L. Mayer, M.D., M.P.H.
Harvard Medical School
Dana Farber Cancer Institute
Dr. Mayer is a consultant for Sanofi-Aventis and Bristol-Myers Squibb.
This CME activity contains discussion of published and/or investigational use of AEE788, axitinib, bevacizumab (Avastin®), trastuzumab (Herceptin®), cediranib (AZD2171; Recentin®), motesanib diphosphate, pazopanib (Votrient®), sorafenib (Nexavar®), sunitinib (Sutent®), SU014813, vatalanib, vandetanib, and VEGF Trap.
David A. Reardon, M.D.
Duke University Medical Center
Dr. Reardon is a consultant for Schering Plough/Merck, Merck KGaA, and Genentech/Roche and is on the speaker’s bureau for Schering Plough/Merck and Genentech/Roche.
This CME activity contains discussion of published and/or investigational use of bevacizumab (Avastin®), cediranib (AZD2171; Recentin®), cilengitide, CNTO 95, erlotinib (Tarceva®), etaracizumab (Abegrin™), and volociximab.
A. Gregory Sorensen, M.D.
Massachusetts General Hospital
Dr. Sorensen receives research funding from AstraZeneca, Genentech, Merck, Novartis, Schering Plough, Siemens, and Takeda; is a consultant for AstraZeneca, Breakaway Imaging, Biogen Idec, Bristol-Myers Squibb, GE Healthcare, Merrimack Pharmaceuticals, Mitsubishi Pharma, Novartis, Olea Medical, Regeneron, Roche, and Siemens Medical; and receives stock/stock options from Breakaway Imaging and Catalyst Medical, LLC.
This CME activity contains discussion of published and/or investigational use of bevacizumab (Avastin®) and cediranib (AZD2171; Recentin®).
Raj K, Tiwari, Ph.D.
New York Medical College
Dr. Tiwari has nothing to disclose with regard to commercial interests.
Peter M. Wilson, Ph.D.
Keck School of Medicine
USC Norris Comprehensive Cancer Center
Dr. Wilson has nothing to disclose with regard to commercial interests.
William W. Li, M.D.,
President, the Angiogenesis Foundation, Editor-in-Chief
Dr. Li has nothing to disclose with regard to commercial interests.
Vickie R. Driver, DPM, M.S., FACFAS, Associate Professor of Surgery, Boston University School of Medicine
Course Director
Dr. Driver receives grant/research support from KCI, sanofi-aventis, 3M, and Baxter. She serves on the Scientific Steering Committee for sanofi-aventis.
Jody Walker, M.S.
BUSM CME Program Manager
BUSM CME Program Manager has nothing to disclose with regard to commercial interests.
Roderick A. Smith, M.S.
Medical Writer, Program Manager, the Angiogenesis Foundation
Medical Writer, Program Manager has nothing to disclose with regard to commercial interests.
PRIVACY POLICY
The Office of Continuing Medical Education adheres to Boston University’s Conditions of Use and Policy on Computing Ethics. <http://www.bu.edu/cme/policies/privacy_policy.html>
Data gathered from participants who participate in Boston University School of Medicine’s (BUSM) Continuing Medical Education Internet-Based CME program is confidential.
Individual identifiable information is not shared with outside parties. Cumulative data may be analyzed by CME personnel, and, upon occasion, by individuals external to BUSM CME in order to determine trends.
THESE MATERIALS AND ALL OTHER MATERIALS PROVIDED IN CONJUNCTION WITH CONTINUING MEDICAL EDUCATION ACTIVITIES ARE INTENDED SOLEY FOR PURPOSES OF SUPPLEMENTING CONTINUING MEDICAL EDUCATION PROGRAMS FOR QUALIFIED HEALTH CARE PROFESSIONALS. ANYONE USING THE MATERIALS ASSUMES FULL RESPONSIBILITY AND RISK FOR THEIR APPROPRIATE USE. TRUSTEES OF BOSTON UNIVERSITY MAKE NO WARRANTIES OR REPRESENTATIONS WHATSOEVER REGARDING THE ACCURACY, COMPLETENESS, CURRENTNESS, NONINFRINGEMENT, MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE OF THE MATERIALS. IN NO EVENT WILL TRUSTEES OF BOSTON UNIVERSITY BE LIABLE TO ANYONE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE MATERIALS. IN NO EVENT SHOULD THE INFORMATION IN THE MATERIALS BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE.
TOPICS AND EDUCATIONAL CONTENT
- Breast cancer
- Renal cell carcinoma
- Ovarian cancer
- Imaging issues with antiangiogenic therapy
- Biomarkers (2 webcasts)
- Chemoprevention
- Brain cancer
SYSTEM REQUIREMENTS
The hardware and software requirements of this webcast are:
- High speed internet connection (NOTE: dialup internet, such as AOL, is not recommended and may result in a poor viewing experience)
- Web browser - Internet Explorer or Mozilla Firefox recommended
- Recent version of Adobe Flash Player (free download or update is available at: http://get.adobe.com/flashplayer)
If you have questions regarding certificates, please contact BUSM CME by email at cme@bu.edu or visit http://www.bu.edu/cme
For questions about this program, please contact the Angiogenesis Foundation at 617-401-2779 or outreach@angio.org.
Copyright 2011 by the Angiogenesis Foundation. All rights reserved.
|
